Free tool
FAERS Monitor: Gimoti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209388 or its brand name (Gimoti, Metoclopramide Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
9,040
Serious
7,706
85% of reports
Hospitalization
3,403
Death reported
1,097
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- tardive dyskinesia2,414
- extrapyramidal disorder1,094
- nausea829
- incorrect drug administration duration691
- off label use605
- diarrhoea507
- vomiting486
- drug ineffective419
- nervous system disorder404
- pyrexia379
- headache371
- tremor365
- dyspnoea351
- fatigue348
- dystonia338
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 52 |
| 2005 | 66 |
| 2006 | 46 |
| 2007 | 56 |
| 2008 | 57 |
| 2009 | 101 |
| 2010 | 243 |
| 2011 | 2,040 |
| 2012 | 331 |
| 2013 | 353 |
| 2014 | 358 |
| 2015 | 77 |
| 2016 | 116 |
| 2017 | 169 |
| 2018 | 207 |
| 2019 | 297 |
| 2020 | 300 |
| 2021 | 586 |
| 2022 | 905 |
| 2023 | 840 |
| 2024 | 782 |
| 2025 | 647 |
| 2026 | 407 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tardive dyskinesiaSignal | 2,414 | 217.6 | 209.9 | 476,424 |
| extrapyramidal disorderSignal | 1,094 | 107.2 | 101.2 | 110,032 |
| incorrect drug administration durationSignal | 691 | 58.6 | 54.5 | 38,137 |
| dystoniaSignal | 338 | 41.2 | 37.1 | 13,015 |
| nervous system disorderSignal | 404 | 30.5 | 27.7 | 11,370 |
| tremorSignal | 365 | 5.1 | 4.6 | 1,215 |
| pyrexiaSignal | 379 | 2.6 | 2.3 | 361 |
| nauseaSignal | 829 | 2.4 | 2.3 | 729 |
| vomitingSignal | 486 | 2.4 | 2.2 | 407 |
| diarrhoea | 507 | 1.8 | 1.7 | 195 |
| off label use | 605 | 1.6 | 1.5 | 144 |
| dyspnoea | 351 | 1.4 | 1.3 | 49 |
| headache | 371 | 1.4 | 1.2 | 39 |
| fatigue | 348 | 1.0 | 0.9 | 1 |
| drug ineffective | 419 | 0.7 | 0.7 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.